Time zero is 24 weeks following cessation of antiviral therapy, at which time it was determined whether patients attained SVR. The survival curves among the patients with chronic hepatitis C virus infection were constructed using a clock-reset approach, by which patients were allowed to switch from the group without SVR to the group with SVR as a result of successful retreatment during follow-up. In these cases, patients in the group without SVR were censored at the time of SVR, which was then redefined as time zero for their further follow-up in the group with SVR. For each virological response group, the survival was compared with matched age-, sex-, and calendar time–specific death rates of the general Dutch population. The P values were based on the Wilcoxon (Gehan) test. The gray areas represent the 95% confidence intervals of cumulative survival among patients with and patients without SVR.
van der Meer AJ, Wedemeyer H, Feld JJ, Dufour J, Zeuzem S, Hansen BE, Janssen HLA. Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. JAMA. 2014;312(18):1927-1928. doi:10.1001/jama.2014.12627
Almost 3 million people in the United States are chronically infected with the hepatitis C virus (HCV).1 The life expectancy of patients with chronic HCV infection is reduced compared with the general population, largely attributable to the development of cirrhosis, liver failure, and hepatocellular carcinoma.2
We3 and others have shown that the hazard of all-cause mortality is lower among patients with chronic HCV infection and advanced hepatic fibrosis if sustained virological response (SVR) is attained, but comparisons have been limited to those without SVR.3 To further investigate the advantage of attaining SVR, we compared overall survival of patients with chronic HCV infection and bridging fibrosis or cirrhosis before therapy (with and without SVR) with that of the general population.
We used data on patients with chronic HCV and advanced hepatic fibrosis from a previous study; the design and characteristics of the population have been described in detail.3 The ethics committees at the individual centers approved the study. Written or oral informed consent was obtained from all patients.
All consecutive patients with chronic HCV monoinfection and biopsy-proven advanced hepatic fibrosis (Ishak fibrosis scores 4, 5, or 6) who initiated interferon-based antiviral therapy between 1990 and 2003 from 5 large hepatology units in Europe and Canada were included. Follow-up started 24 weeks after cessation of antiviral treatment, at which time achievement of SVR (defined as HCV RNA negativity in a blood sample using molecular assays) was determined. If the survival status as of January 1, 2010, could not be determined from retrospective chart review, the patient, primary care physician, or both were recontacted. If this was not successful by October 2011, the follow-up was considered incomplete.
For each virological response group, the observed overall survival was compared with the expected survival from matched age-, sex- and calendar time–specific death rates of the general population in the Netherlands, which were obtained from the bureau of statistics, using the life table method and the Wilcoxon (Gehan) test. The statistical tests were 2-sided and P < .05 was considered statistically significant. SPSS version 21.0 (SPSS Inc) was used for the statistical analyses.
In total, 530 patients were followed up for a median of 8.4 years (interquartile range [IQR], 6.4-11.4 years). Follow-up was complete in 454 patients (86%). The median age was 48 years (IQR, 42-56 years), 369 patients (70%) were male, and 192 attained SVR (36%). Thirteen patients with SVR died, resulting in a cumulative 10-year overall survival of 91.1% (95% CI, 85.5%-96.7%), which did not differ significantly from the age- and sex-matched general population (P = .57) (Figure).
In contrast, 100 patients without SVR died. The cumulative 10-year survival was 74.0% (95% CI, 71.6%-79.8%), which was significantly lower compared with the matched general population (P < .001).
Among patients with chronic HCV infection and bridging fibrosis or cirrhosis, attaining SVR was associated with survival comparable with that of the general population, whereas not attaining SVR was associated with reduced survival. The excellent survival among patients with advanced liver disease and SVR might be explained by the associations between SVR and regression of hepatic inflammation and fibrosis, reduced hepatic venous pressure gradient, reduced occurrence of hepatocellular carcinoma and liver failure, as well as reduced occurrence of diabetes mellitus, end-stage renal disease, and cardiovascular events.4,5 Even though patients with cirrhosis and SVR remain at risk for hepatocellular carcinoma, the annual hepatocellular carcinoma incidence is low and survival is substantially better compared with those without SVR.6 Competing risks could also contribute.
Our study is limited by its retrospective design and restriction to general population data that only were available for the Netherlands. However, life expectancy in the Netherlands is similar to other participating countries so this is not expected to have had a major influence on our results. Also, all patients received interferon-based therapy. Thus, these results need to be confirmed when interferon-free therapy is widely used because these highly effective regimens may be administered to patients with more comorbidity and more advanced liver disease.
Corresponding Author: Adriaan J. van der Meer, MD, PhD, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands (email@example.com).
Author Contributions: Drs van der Meer and Janssen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Van der Meer, Dufour, Zeuzem, Hansen, Janssen.
Drafting of the manuscript: Van der Meer, Dufour, Janssen.
Critical revision of the manuscript for important intellectual content: Van der Meer, Wedemeyer, Feld, Zeuzem, Hansen, Janssen.
Statistical analysis: Van der Meer, Hansen.
Obtained funding: Van der Meer, Janssen.
Administrative, technical, or material support: Wedemeyer, Feld, Dufour.
Study supervision: Wedemeyer, Feld, Zeuzem, Hansen, Janssen.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and declared that they did not receive financial support from industrial partners for the current work. Dr van der Meer reported receiving financial compensation for lecture activities from Merck Sharp & Dohme and Gilead. Dr Wedemeyer reported receiving financial compensation for serving as a consultant or for lecture activities from Roche, Merck Sharp & Dohme, Abbott, Novartis, Bristol-Myers Squibb, and Gilead; and institutional grants from Roche, Merck Sharp & Dohme, Abbott, Novartis, Bristol-Myers Squibb, and Gilead. Dr Feld reported receiving financial compensation for serving as a consultant, for lecture activities, and for development of educational presentations from Hoffmann-LaRoche, Merck, Gilead, Tibotec, Abbott, Vertex, and Clinical Care Options. Dr Dufour reported receiving financial compensation for lecture activities or travel accommodations from Bayer, Roche, and Novartis; and institutional fees for a serving on boards from Roche, Bristol-Meyers Squibb, Gilead, Novartis, and Transgene. Dr Zeuzem reported receiving financial compensation for serving as a consultant or for lecture activities from Abbott, Achillion, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Merck, Novartis, Roche, Santaris, Janssen, Idenix, Presidio, and Vertex. Dr Hansen reported receiving financial compensation for lecture activities from Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead, and Janssen. Dr Janssen reported receiving financial compensation for serving as a consultant from Roche, Merck, Abbott, Santaris, Anadys, Medtronic, Tibotec, Bristol-Myers Squibb, and Gilead; and institutional research grants from Roche, Merck, Abbott, Santaris, Anadys, Medtronic, and Tibotec.
Funding/Support: This study was funded by the Foundation for Liver and Gastrointestinal Research in Rotterdam, the Netherlands.
Role of the Funder/Sponsor: The Foundation for Liver and Gastrointestinal Research had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We acknowledge the following persons for their contributions to the study: Bart J. Veldt, MD, PhD, and Robert J. de Knegt, MD, PhD (Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands); Andres Duarte-Rojo, MD (Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock); Michael P. Manns, MD, PhD (Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany); Frank Lammert, MD, PhD (Department of Medicine II, Saarland University Medical Center, Hamburg, Germany); and W. Peter Hofmann, MD, PhD (Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany). These individuals were not compensated for their contributions outside of their salaries.